5 in 1 meningitis vaccine! GlaxoSmithKline's MenABCWY III Clinical Program vaccinated the first subjects!

August 20, 2020 // -- GlaxoSmithKline (GSK) recently announced that it has vaccinated the first subjects in its Phase III clinical project for the MenabcWY vaccine, which aims to compare MenABCWY with Bexsero and Menveo, the company's two meningococcal vaccines already on the market.
the first trial subjects in the Phase III trial, MenABCWY was immunized for the first time, marking an important milestone in GSK's leadership in meningitis vaccine development.
first approved in 2010 and 2013, GSK has distributed more than 58 million doses of Menveo (A, C, Y, W-135 serum meningococcal vaccine) and more than 52 million doses of Bexsero (group B meningococcal vaccine).
GSK Senior Vice President and Head of Vaccine Research and Development Emmanuel Hanon said, "The late-stage clinical phase of MenABCWY, a 5-in-1 candidate vaccine, marks an important step towards our goal of reducing meningococcal disease worldwide.
this candidate vaccine builds on the traditions of Bexsero and Menveo, we would like to thank all the researchers, medical partners, advocates and families around the world who wish the research to be successful.
" project's first Phase III study (NCT04502693) will recruit 3,650 subjects aged 10-25 in the United States, Europe, Turkey and Australia to assess the safety, tolerance and immunogenicity of MenABCWY and the two meningococcal vaccines on the market, Bexsero and Menveo, in adolescents and young adults.
If GSK's 5-in-1 meningitis vaccine MenABCWY is successful in this Phase III clinical trial, it will be able to help protect adolescents and young people from invasive meningococcal disease (IMD) with fewer injections.
five meningitis serum groups (A, C, W, Y, B) have led to almost all IMD cases, but no 5-in-1 vaccine is available. Charles P. Andrews, clinical research director of the Diagnostic Research Group in San Antonio, Texas, one of the investigators in the
study, said: "The meningitis vaccine currently approved by the FDA can help protect young people who complete a four-shot immunization program during adolescence, but unfortunately only a small percentage of people have completed a four-shot immunity program.
5-in-1 meningitis vaccine MenABCWY has the potential to reduce the number of injections, thereby increasing immunization completion rates.
" invasive meningococcal disease (Photo: gskpro.com) In the United States, menACWY vaccine immunization recommendations are for 11-12 year olds to get boosted immune injections at age 16, but a 2018 study showed that only 50.8 percent of older teens received booster injections.
MenB vaccine is immunized in adolescents aged 16-23 years (preferred 16-18 years old) based on "common clinical decisions" between medical providers and parents, but MenB coverage of at least one shot of MenB immunization in 17-year-olds is only 17.2%.
from March 2011 to March 2019, MenB was 100% responsible for meningococcal outbreaks at U.S. universities, with a high-risk population of about 253,000 students, involving 13 campuses, 50 cases and 2 deaths. Dr. Barbara Howe, Vice President and Director of Clinical Research, Development and Medical Affairs at
GSK Vaccines, said, "We are pleased to reach this important milestone in the development of MenABCWY, a 5-in-1 vaccine that offers the possibility of adopting a product to help prevent all five vaccine preventable serum groups.
this reduces the complexity and potential confusion of requiring two different types of vaccines, with fewer immunizations.
" () Original source: GSK announces first participant in the phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine candidate.